The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A few studies using this approach have shown positive outcomes in patients with AML and patients with MDS with DNMT3A mutations, although the mechanisms are poorly understood (46–48).”
From Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway (2023) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russler-Germain, D. A., Spencer, D. H., Young, M. A., Lamprecht, T. L., Miller, C. A., Fulton, R., Meyer, M. R., Erdmann-Gilmore, P., Townsend, R. R., Wilson, R. K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.010 · Cited by 452 · cited 1×
“Overall rate of CR 23% 43% 28% (CR+CRi) Median/mean Median: 2 (1-23) Median: 4 (1-12) Median: 3 (1-23) number of HMA Mean: 4.”
Research works printed but not linked: 14
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
- Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, ran- domized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
- Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291- 299.
- Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
- Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152.
- Emadi A, Faramand R, Carter-Cooper B, et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. 2015;90(5):E77-79.
- DiNardo CD, Patel KP, Garcia-Manero G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014;55(8):1925-1929.
- Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5):1106-1107.
- Sallman DA, Komrokji R, Vaupel C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodys- plastic syndromes. Leukemia. 2016;30(3):666-673.
- Cheng DT, Cheng J, Mitchell TN, et al. Detection of mutations in myeloid malignancies through paired-sample analysis of micro- droplet-PCR deep sequencing data. J Mol Diagn. 2014;16(5):504-518.
- Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014;99(4):613-619.
- Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
- Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
- Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of inte- grated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
Cited by
Hunter, A. M., Komrokji, R. S., Yun, S., Al Ali, N., Chan, O., Song, J., Hussaini, M., Talati, C., Sweet, K. L., Lancet, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003508 · Cited by 76
Self-citationLoss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway
Palam, L. R., Ramdas, B., Pickerell, K., Pasupuleti, S. K., Kanumuri, R., Cesarano, A., Szymanski, M., Selman, B., Dave, U. P., Sandusky, G., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163864 · Cited by 13
Metadata
- Authors
- Coombs, C. C., Sallman, D. A., Devlin, S. M., Dixit, S., Mohanty, A., Knapp, K., Al Ali, N. H., Lancet, J. E., List, A. F., Komrokji, R. S., Padron, E., Arcila, M. E., Klimek, V. M., van den Brink, M. R. M., Tallman, M. S., Levine, R. L., Rampal, R. K., & Rapaport, F.
- Venue
- Haematologica
- Published
- 2016-07-14
- Volume
- 101
- Issue
- 11
- Pages
- e457-e460
- ISSN
- 0390-6078
- 1592-8721
- Cited by
- 39
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. https://app.cochat.ai/papers/10.3324/haematol.2016.148999
- The paper
- Coombs, C. C., Sallman, D. A., Devlin, S. M., Dixit, S., Mohanty, A., Knapp, K., Al Ali, N. H., Lancet, J. E., List, A. F., Komrokji, R. S., Padron, E., Arcila, M. E., Klimek, V. M., van den Brink, M. R. M., Tallman, M. S., Levine, R. L., Rampal, R. K., & Rapaport, F. (2016). Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. https://doi.org/10.3324/haematol.2016.148999
